2-氯脱氧腺苷间歇性2小时静脉输注治疗110例难治性或未经治疗的B细胞慢性淋巴细胞白血病患者。

Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.

作者信息

Robak T, Błasinka-Morawiec M, Krykowski E, Kasznicki M, Płuzanska A, Potemski P, Hellmann A, Zaucha J M, Lewandowski K, Dmoszynska A, Hansz J, Komarnicki M, Konopka L, Durzynski T, Ceglarek B, Sikorska A, Kotlarek-Haus S, Mazur G, Urasinski I, Zdziarska B, Maj S, Kopec I, Skotnicki A B, Dwilewicz-Trojaczek J, Grieb P

机构信息

Department of Hematology, Medical University of Lódz, Poland.

出版信息

Leuk Lymphoma. 1996 Aug;22(5-6):509-14. doi: 10.3109/10428199609054790.

DOI:10.3109/10428199609054790

PMID:8882965

Abstract

The purpose of our study was to determine the effectiveness of 2-CdA in 2-hour intravenous infusions in the treatment of B-CLL. One hundred and ten patients with B-CLL received 1 to 10 courses of 2-CdA (median 2.5) at a dosage of 0.12 mg/kg daily for 5 consecutive days. Eighteen of them were untreated and 92 relapsed or became refractory to previous therapeutic modalities. Complete remission (CR) was achieved in 8 (7.3%) and partial remission (PR) in 35 patients (31.8%) giving an overall response rate of 39.1%. In 3 patients, cross-resistance to fludarabine was noticed. Toxic effects of 2-CdA were more frequently observed in previously treated patients. Hemorrhagic complications due to drug-induced thrombocytopenia were noticed in 25 (22.7%) and severe infections including sepsis in 14 (12.7%) patients.

摘要

我们研究的目的是确定2-氯脱氧腺苷（2-CdA）持续2小时静脉输注治疗B细胞慢性淋巴细胞白血病（B-CLL）的有效性。110例B-CLL患者接受了1至10个疗程的2-CdA治疗（中位数为2.5个疗程），剂量为每日0.12mg/kg，连续5天。其中18例未接受过治疗，92例对先前的治疗方式复发或难治。8例（7.3%）达到完全缓解（CR），35例（31.8%）达到部分缓解（PR），总缓解率为39.1%。3例患者出现对氟达拉滨的交叉耐药。2-CdA的毒性作用在先前接受过治疗的患者中更常观察到。25例（22.7%）患者出现因药物诱导的血小板减少导致的出血并发症，14例（12.7%）患者出现包括败血症在内的严重感染。